Search

Your search keyword '"Dumont, Aurélie"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Dumont, Aurélie" Remove constraint Author: "Dumont, Aurélie"
46 results on '"Dumont, Aurélie"'

Search Results

3. Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis

6. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

7. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

8. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

9. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

13. Supplementary Figure 1 from Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

14. Supplementary Methods from Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

15. Data from Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

16. Supplementary Figure Legend from Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

17. Développement d’un score non commercial d’instabilité génomique pour les cancers ovariens

19. Abstract 2022: Model-informed pediatric drug development: oral vinorelbine in low-grade glioma as a case study

20. A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers

21. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

24. Les céramiques communes antiques d’Italie et de Narbonnaise

25. Les productions de céramique à pâte calcaire entre la fin du Ier s. avant n. è. et la fin du Ier s. de n. è. à partir des ateliers de Saint-Lambert / Valescure et de Sainte-Croix 2 (Fréjus, Var)

26. LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers

27. Etat des connaissances de l'occupation romaine sur la commune de Saint-Raphaël (Var)

28. Fréjus – Les Horts

29. Draguignan – Parking Bontemps

30. Cavalaire-sur-Mer – Avenue Pierre et Marie Curie

31. Les fours de potiers gallo-romains de St-Lambert et de Valescure à Fréjus (Var)

32. Abstract B233: The depletion of LRP5, unlike that of LRP6, promotes apoptosis in triple-negative breast cancer cells, making it an interesting therapeutic target.

33. TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer

34. Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

35. Abstract 2938: Polo-like kinase 1: a potential therapeutic target for the management of patients with triple negative breast cancer

36. Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells

40. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

41. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

42. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

43. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

44. An indie I admire….

45. [Implementation of edoxaban anti-Xa activity assay in a hospital laboratory and evaluation of its analytical performance].

46. Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.

Catalog

Books, media, physical & digital resources